EDMONTON, ALBERTA--(Marketwire - November 14, 2007) - ViRexx Medical Corp. (TSX: VIR) (AMEX: REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumours, today announced its financial and operational results for the three-month and nine-month periods ended September 30, 2007.
